Toggle light / dark theme

Butterfly gliomas: to biopsy or to ablate cohort study NeuroOncology

Butterfly gliomas are an aggressive subset of high-grade glioma characterized by bilateral hemispheric involvement. These patients often only receive biopsy followed by chemoradiation rather than surgical resection. Laser interstitial thermal therapy (LITT) provides a minimally invasive alternative that can improve survival.

We retrospectively compare outcomes in biopsy alone versus LITT cohorts. Demographic characteristics, perioperative outcomes, and survival metrics were analyzed. Within the LITT cohort, procedural and volumetric analyses were performed to examine the relationship between extent of ablation (EOA), residual tumor burden (RTB).

Of 44 patients, 15 underwent biopsy only and 29 received LITT was associated with a longer median overall survival compared to biopsy (14.86 versus 4.93 months, p = 0.0489), and median progression-free survival (4.67 versus 2.53 months, p = 0.0389). Within the LITT cohort, larger preoperative tumor volumes were associated with lower EOA (r²=0.46, p = 0.0002) and a higher RTB (r2 = 0.90, p = 0.0001). Longer ablation times correlated with a larger EOA (r2 = 0.21, p = 0.0320). Neither EOA nor RTB were associated with survival. Postoperative KPS improvement correlated with improved OS after multivariable Cox proportional hazards analysis (HR (death) = 0.93, 95%CI:0.87–0.99, p = 0.026), with a similar trend in PFS. Total operating room time was longer in the LITT group (median 4.0 vs. 2.57 h, p = 0.0034), while time-to-chemoradiation, ICU stay, and hospital stay were comparable. Post-operative re-admissions and complications were not statistically different between groups.

CRISPR-Cas orchestrates a layered defense network to fight bacterial viruses

All cellular life-from humans to bacteria-possesses two layers of immunity: innate and adaptive. Scientists have long understood how these two types of immunity work together in higher organisms but not in the microbial world.

Bacteria and archaea use CRISPR-Cas as their sole form of adaptive immunity-a precise, sequence-specific defense that remembers past invaders. But what about innate immunity? Now, a study led by Prof. LI Ming from the Institute of Microbiology of the Chinese Academy of Sciences (CAS) reveals that CRISPR-Cas plays a broader role. Rather than acting alone like a solitary sniper shooting at phages, it also serves as a central command center, directing a network of diverse innate immune systems.

This work was published in Nature on July 22.

Age-Reversing Stem Cell Treatment Succeeds in Human Trial | Dr Koji Tanabe

Discover how original Yamanaka co-author Dr. Koji Tanabe uses automated iPSC cassettes and autologous stem cell secretomes to reverse cellular aging and repair damaged joints.

Some links are affiliate links so we will earn a commission when they are used to purchase products.

🧬 SUPPORT THE CHANNEL & LONGEVITY PARTNERS
If you would like to support our channel please consider joining our Patreon / modernhealthspan.
~~~~~~~~~~~~~~
Renue By Science (10% off: MHS) https://tinyurl.com/bdew4bfs NMN Powder • Lipo NR
BiOptimizers (15% off: MHBIO) https://bit.ly/47VAa8f — Magnesium Breakthrough, Gluten Guardian.
Seeking Health (10% off: Richard10) https://crrnt.app/SEEK/-dm0MyrQ, Histamine Nutrients https://crrnt.app/SEEK/EpM7paAO
Stemregen (15% off: MODERN) US only https://tinyurl.com/45z968yr.
AX3 Life (20% off: MODERN20) https://tinyurl.com/2t3w26nw — Astaxanthin.
Viome Full Body Intelligence https://viomehq.sjv.io/X4rkBg.
n1o1 (10% off: Modern) https://tidd.ly/3IczGRW — Nitric Oxide Lozenges.
Qualia (15% off: MODERN) Creatine+ https://tinyurl.com/mr3z35jd Senolytic https://bit.ly/4jlaibe.
Qitone (10% off: HEALTH10) https://tidd.ly/4jGklry Qitone Esters Powder.
MitoQ https://tinyurl.com/5n93fm3f MitoQ Pure https://tinyurl.com/3hxy9s7x.
Wellness Extract (10% off: MODERNWE) http://wellnessextract.com/RICHARDWE Geranylgeraniol • Vit E
Oxford Healthspan (15% off: MHS) https://tinyurl.com/hrxfnzpn — Spermidine.
ProHealth (15% off: MODERN) https://prohealth.pxf.io/aObQRR NMNH 500mg.
~~~~~~~~~~~~~~

In this landmark episode of Modern Healthspan, we sit down with Dr. Koji Tanabe, founder and CEO of iPS, Inc. and co-author of the historic 2007 Nobel Prize-winning paper on human-induced pluripotent stem cells (iPSCs). Dr. Tanabe shares how twenty years of technological advancement have raised iPSC reprogramming efficiency from under 1% to over 80%, while cutting manufacturing costs through automated cleanroom cassettes. We discuss practical longevity applications available today, including autologous stem cell banking from a simple blood draw, secretome extract therapies for joint and skin rejuvenation, and Japan’s approval of iPSC-derived heart tissue. Finally, Dr. Tanabe offers a critical scientific perspective on in vivo partial reprogramming, detailing the cellular identity loss and tumor risks associated with OSK gene delivery. Watch now to learn where stem cell age reversal truly stands today.

📚 Chapters.
00:00 — How the 2007 Yamanaka Breakthrough Reverses Cell Age.
09:58 — Cellular Reprogramming in Nature (Salamanders & Limbs)
15:01 — From 1% to 90%: Scaling Transfection Efficiency.
19:57 — Mass Production: Automated Cassettes for Stem Cells.
24:57 — Slashed Costs: Disrupting the $10M Treatment Price Tag.
29:58 — Retrovirus Danger: Preventing Toxic Contamination.
35:01 — Japan’s Law: Safety Testing & Rejuvenation Services.
39:58 — Next-Gen Immune Therapy: iPSCs vs Cancer & Aging.
44:59 — The In-Vivo Reprogramming Risk: Why It Fails.
49:59 — Infinite Cellular Supply: Pluripotency’s Power.
54:57 — Beyond Reprogramming: Solving the Extracellular Matrix.

Medical Disclaimer:

Team uses AlphaFold AI to redesign geneediting proteins to make them safer

A couple of decades after the discovery of systems that could selectively target DNA, we’re starting to see the first therapies based on gene editing. One challenge these developments have faced is safety. While we can make them pretty specific to the gene we want edited, the human genome is very large, and even rare DNA sequences can appear a couple of times by chance.

As a result, all the original gene-editing systems had known rates of what are called off-target effects, in which they simply edit the wrong sequence. This may be a low-probability event, but edit enough cells—and therapies generally have to edit many—and errors become inevitable.

A lot of effort has gone into finding ways to minimize or eliminate off-target edits. In a recent issue of Nature, researchers described modifying the AI protein-folding software AlphaFold to help identify key areas of gene-editing proteins responsible for off-target effects. Those areas were then modified to reduce the problems.

Giving antibodies ‘eyes’ may help target hidden KRAS mutations in cancer cells

Antibodies are like “guided missiles” that find and attack cancer cells, but cancer-causing mutations inside cells have remained a “blind spot” for treatment because antibodies cannot reach them. KAIST researchers have now succeeded in precisely targeting intracellular cancer mutations using a newly designed antibody created through computational methods.

The work is published in the journal Molecular Therapy.

This achievement is expected to open a new path toward next-generation precision therapies for difficult-to-treat cancers, going beyond the limitations of conventional antibody treatments.

Injectable biomaterial harnesses the immune system to promote brain repair after stroke

Biomedical engineers at Duke University have developed an injectable biomaterial that helps transform the cavity left behind after a stroke caused by a blood clot into an environment more supportive of repair. By recruiting the body’s own immune cells, the treatment promoted the growth of new blood vessels, supported neural remodeling and improved motor performance in mice. The work appears in Cell Biomaterials.

Every year, millions of people experience strokes caused by blood clots, called ischemic strokes. Immediate treatments, including clot-dissolving drugs and mechanical removal of the clot, can restore blood flow and preserve threatened brain tissue. But these treatments cannot replace tissue that has already been lost.

Large strokes can result in substantial tissue loss and leave behind a cavity at the site of the injury. After the clot is removed, recovery relies largely on rehabilitation, which helps surviving brain circuits adapt but does not directly repair the damaged area.

Learning a new skill triggers both temporary cell swelling and lasting structural growth in the human brain

When you learn a new skill, your brain undergoes physical changes. A new study using advanced MRI technology reveals that mastering a task triggers two distinct, unexpected cellular reactions that reshape our understanding of human neuroplasticity.

Senescent cell heterogeneity in brain aging and neurodegenerative disease

This review by Graves et al. synthesizes emerging evidence that senescent brain cells are heterogeneous, dynamic, and context dependent, highlighting determinants of diverse programs and emphasizing integration of single-cell-and spatial-omics with mouse studies to facilitate mechanistic insights and possible therapeutics.

Inside the World’s First Age Reversal Trial | Lifespan with Dr. David Sinclair — S2, Ep. 4

At Lifespan, our mission is to help you and your loved ones live your longest, healthiest lives while supporting medical research into breakthroughs to improve all lives.

We’re building the world’s largest longevity community: Join us at https://lifespan.com.

Follow us on YouTube, Apple, and Spotify for new Lifespan episodes every 2 weeks.

In this episode of Lifespan, Dr. David Sinclair, A.O., Ph.D. – Professor of Genetics at Harvard Medical School and pioneer in longevity research – explores the science of eye aging, vision loss, and emerging strategies to preserve vision throughout life.

Dr. Sinclair shares an inside update on ER-100, including his team’s successful restoration of vision in non-human primates and the launch of the world’s first FDA-cleared age reversal human clinical trial. This Phase 1 clinical trial will evaluate the safety of epigenetic cellular restoration as a therapy.

Additionally, drawing on decades of research, Dr. Sinclair explains why the eyes may offer one of the earliest windows into biological aging, how everyday factors such as sleep position, alcohol consumption, and intraocular pressure influence long-term eye health, and what the latest evidence reveals about nutrition, supplements, and the connection between the eyes and the brain.

Why the Next 10 Years May Add 50 to Your Lifespan | Dr. Derya Unutmaz

The next 10 years may add decades to human lifespan by compressing the time it takes to understand, treat, and prevent disease. In this episode, Dr. Derya Unutmaz explains why accelerating AI could transform drug discovery, shorten clinical trials, and push cancer treatment toward increasingly personalized interventions. He also reframes AI not as an existential threat, but as a medical enabler that doctors may soon be ethically obligated to use.

Get weekly, protocol-driven research breakdowns from Dr. Rhonda Patrick to advance healthspan, longevity, brain health, and resilience: https://www.foundmyfitness.com/newsle… 00:00:00 Introduction 00:02:16 Why the next 10 years may add 50 to your lifespan 00:06:25 How AI is transforming drug discovery 00:11:55 Could digital twins shorten clinical trials? 00:14:31 Can AI predict drug safety and efficacy? 00:18:46 Have we already reached AGI? 00:24:28 Why AI may be medicine’s greatest force multiplier 00:30:41 Can AI replicate a scientist’s biological intuition? 00:37:22 Is it malpractice for doctors not to use AI? 00:43:24 What happens when AI monitors disease in real time? 00:46:58 Which AI models should doctors trust? 00:52:34 Claude vs. GPT—does the model matter for diagnosis? 00:56:04 Generalist vs. specialized AI—which works better in medicine? 00:59:30 Why cancer is so hard to cure 01:03:24 Could cancer be curable within a decade? 01:07:35 Can AI design cancer treatments on demand? 01:09:37 How AI could curb overtreatment and side effects 01:12:33 Predicting cancer years before it forms—is it possible? 01:18:55 Why biology could go exponential with AI 01:24:04 Why aging may be easier to prevent than reverse 01:29:56 Can the body be engineered to resist aging? 01:35:13 Can AI model how gene therapy will behave? 01:39:17 What people who reach 110+ reveal about Human 2.0 01:41:27 From Dolly to Yamanaka factors—the case for cellular age reversal 01:46:02 Why full-body rejuvenation is an engineering problem 01:53:49 What happens when AI reasons longer about biology? 01:56:31 The biosecurity dilemma of powerful AI 02:01:17 What should we actually measure to track aging? 02:07:40 How old immune cells distort aging clocks 02:10:28 Why reversing brain aging is uniquely difficult 02:16:55 The ultimate prompt for extending lifespan 02:18:56 What data does a true digital twin need? 02:23:38 How to build a mini digital twin today 02:28:32 How to give AI a long-term memory of your data 02:31:39 Why personal baselines matter for AI advice Derya Unutmaz, M.D. X: https://twitter.com/DeryaTR_ EPISODE LINKS Show notes & transcript: https://www.foundmyfitness.com/episod… PODCAST INFO Apple Podcasts: https://podcasts.apple.com/us/podcast… Spotify: https://open.spotify.com/episode/4BPh… SUPPORT MY MISSION Access more than 130 episodes of my premium podcast (The Aliquot) when you become a FoundMyFitness Premium Member: https://www.foundmyfitness.com/crowds… #ai.

CHAPTERS:
00:00:00 Introduction.
00:02:16 Why the next 10 years may add 50 to your lifespan.
00:06:25 How AI is transforming drug discovery.
00:11:55 Could digital twins shorten clinical trials?
00:14:31 Can AI predict drug safety and efficacy?
00:18:46 Have we already reached AGI?
00:24:28 Why AI may be medicine’s greatest force multiplier.
00:30:41 Can AI replicate a scientist’s biological intuition?
00:37:22 Is it malpractice for doctors not to use AI?
00:43:24 What happens when AI monitors disease in real time?
00:46:58 Which AI models should doctors trust?
00:52:34 Claude vs. GPT—does the model matter for diagnosis?
00:56:04 Generalist vs. specialized AI—which works better in medicine?
00:59:30 Why cancer is so hard to cure.
01:03:24 Could cancer be curable within a decade?
01:07:35 Can AI design cancer treatments on demand?
01:09:37 How AI could curb overtreatment and side effects.
01:12:33 Predicting cancer years before it forms—is it possible?
01:18:55 Why biology could go exponential with AI
01:24:04 Why aging may be easier to prevent than reverse.
01:29:56 Can the body be engineered to resist aging?
01:35:13 Can AI model how gene therapy will behave?
01:39:17 What people who reach 110+ reveal about Human 2.0
01:41:27 From Dolly to Yamanaka factors—the case for cellular age reversal.
01:46:02 Why full-body rejuvenation is an engineering problem.
01:53:49 What happens when AI reasons longer about biology?
01:56:31 The biosecurity dilemma of powerful AI
02:01:17 What should we actually measure to track aging?
02:07:40 How old immune cells distort aging clocks.
02:10:28 Why reversing brain aging is uniquely difficult.
02:16:55 The ultimate prompt for extending lifespan.
02:18:56 What data does a true digital twin need?
02:23:38 How to build a mini digital twin today.
02:28:32 How to give AI a long-term memory of your data.
02:31:39 Why personal baselines matter for AI advice.

Derya Unutmaz, M.D.
X: https://twitter.com/DeryaTR_

EPISODE LINKS
Show notes & transcript: https://www.foundmyfitness.com/episod…

/* */